Table 3 Summary of the administration of the clinical trials
Items | Definition | All cases completed | Not all cases completed | p value |
|---|---|---|---|---|
n = 95 | n = 47 | |||
n (%) | n (%) | |||
Clinical trial with an agreed PIP | Yes | 18 (18.9) | 13 (27.7) | 0.24 |
Sponsor type | Commercial | 87 (91.6) | 47 (100.0) | 0.10 |
Clinical trial with substantial protocol amendments | Yes | 71 (74.7) | 31 (66.6) | 0.27 |
Clinical trial with no protocol amendments after starting trials | Yes | 41 (43.2) | 20 (42.6) | 0.94 |
Global interruptions of the clinical trial | Yes | NA | 7 (14.9) | NA |
Clinical trial status | ||||
Not authorized | Yes | NA | 4 (8.5) | NA |
Temporarily halted | Yes | NA | 2 (4.3) | NA |
Prematurely ended | Yes | NA | 43 (91.5) | NA |